Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in xenograft models and has been successful in clinical trials with renal cell carcinoma (RCC) and several other tumour types. ==Medical uses== A Phase II clinical trial showed...
Found on


A substance being studied in the treatment of some types of cancer. Axitinib blocks growth factor receptors and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.
Found on
No exact match found